Cleveland BioLabs (CBLI -3%) slips after saying it's received the end-of-Phase 2 meeting minutes...
Monday, October 1, 2012, 3:20 PM ETCleveland BioLabs (CBLI -3%) slips after saying it's received the end-of-Phase 2 meeting minutes from the FDA, along with an advice letter which clarifies the remaining clinical study protocols for the development of its Entolimod as a radiation countermeasure. The firm says the agency is committed to moving the Entolimod program forward, but it has some requests regarding several aspects of the proposed plan for dose conversion.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles